23948sdkhjf
Log in or create to bookmark articles
Get access to all content on Life Science Focus
No commitment or card information required
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

AstraZeneca's new blood pressure drug recommended for EU approval

AstraZeneca's blood pressure drug Baxfendy (baxdrostat) has received a positive recommendation from the European Medicines Agency's CHMP, paving the way for EU approval.
Advertisement

Baxfendy has been recommended for the treatment of adults with arterial hypertension that is not adequately controlled by at least two antihypertensive medicines.

If approved, it will become the first aldosterone synthase inhibitor (ASI) on the EU market. Baxfendy works by inhibiting the production of aldosterone, a hormone that plays an important role in regulating blood pressure.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.063|